Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Turnstone Biologics to Participate in Upcoming Investor Conferences By: Turnstone Biologics Corp. via GlobeNewswire February 21, 2024 at 06:00 AM EST SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that members of its senior management team will participate in the following investor conferences: TD Cowen 44th Annual Global Health Care Conference Type: Presentation and one-on-one investor meetingsSpeaker: Sammy Farah, M.B.A., Ph.D., President and Chief Executive OfficerDate: Wednesday, March 6, 2024Presentation Time: 2:10pm ET / 11:10am PTLocation: Boston, MA Leerink Partners Global Biopharma Conference 2024 Type:Date:Location: One-on-one investor meetingsWednesday, March 13, 2024Miami, FL A live webcast of the presentation may be accessed on the Events page of Turnstone’s Investor Relations website at https://ir.turnstonebio.com, where a replay will also be available for a limited period. Institutional investors interested in meeting with members of Turnstone’s senior management team during the conferences may contact their respective representatives at TD Cowen and Leerink Partners for further information. About TurnstoneTurnstone Biologics is a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. Turnstone’s novel TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TIL, and is designed to overcome the limitations of first-generation bulk TIL that have demonstrated objective responses only in limited tumor types. Turnstone’s most advanced program, TIDAL-01, is currently being evaluated in two Phase 1 studies in patients with melanoma, breast cancer and colorectal cancer, and the Company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. For additional information about Turnstone, please visit www.turnstonebio.com, and follow us on LinkedIn. Contact Ahmed AneiziInvestor RelationsTurnstone Biologics(347) 897-5988ahmed.aneizi@turnstonebio.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Turnstone Biologics to Participate in Upcoming Investor Conferences By: Turnstone Biologics Corp. via GlobeNewswire February 21, 2024 at 06:00 AM EST SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that members of its senior management team will participate in the following investor conferences: TD Cowen 44th Annual Global Health Care Conference Type: Presentation and one-on-one investor meetingsSpeaker: Sammy Farah, M.B.A., Ph.D., President and Chief Executive OfficerDate: Wednesday, March 6, 2024Presentation Time: 2:10pm ET / 11:10am PTLocation: Boston, MA Leerink Partners Global Biopharma Conference 2024 Type:Date:Location: One-on-one investor meetingsWednesday, March 13, 2024Miami, FL A live webcast of the presentation may be accessed on the Events page of Turnstone’s Investor Relations website at https://ir.turnstonebio.com, where a replay will also be available for a limited period. Institutional investors interested in meeting with members of Turnstone’s senior management team during the conferences may contact their respective representatives at TD Cowen and Leerink Partners for further information. About TurnstoneTurnstone Biologics is a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. Turnstone’s novel TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TIL, and is designed to overcome the limitations of first-generation bulk TIL that have demonstrated objective responses only in limited tumor types. Turnstone’s most advanced program, TIDAL-01, is currently being evaluated in two Phase 1 studies in patients with melanoma, breast cancer and colorectal cancer, and the Company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. For additional information about Turnstone, please visit www.turnstonebio.com, and follow us on LinkedIn. Contact Ahmed AneiziInvestor RelationsTurnstone Biologics(347) 897-5988ahmed.aneizi@turnstonebio.com
SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that members of its senior management team will participate in the following investor conferences: TD Cowen 44th Annual Global Health Care Conference Type: Presentation and one-on-one investor meetingsSpeaker: Sammy Farah, M.B.A., Ph.D., President and Chief Executive OfficerDate: Wednesday, March 6, 2024Presentation Time: 2:10pm ET / 11:10am PTLocation: Boston, MA Leerink Partners Global Biopharma Conference 2024 Type:Date:Location: One-on-one investor meetingsWednesday, March 13, 2024Miami, FL A live webcast of the presentation may be accessed on the Events page of Turnstone’s Investor Relations website at https://ir.turnstonebio.com, where a replay will also be available for a limited period. Institutional investors interested in meeting with members of Turnstone’s senior management team during the conferences may contact their respective representatives at TD Cowen and Leerink Partners for further information. About TurnstoneTurnstone Biologics is a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. Turnstone’s novel TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TIL, and is designed to overcome the limitations of first-generation bulk TIL that have demonstrated objective responses only in limited tumor types. Turnstone’s most advanced program, TIDAL-01, is currently being evaluated in two Phase 1 studies in patients with melanoma, breast cancer and colorectal cancer, and the Company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. For additional information about Turnstone, please visit www.turnstonebio.com, and follow us on LinkedIn. Contact Ahmed AneiziInvestor RelationsTurnstone Biologics(347) 897-5988ahmed.aneizi@turnstonebio.com